CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer

Comment: Keynote 522 trial

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma

Ovarian highlights from ESMO 2019

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Comment: Immunotherapy combination for advanced NSCLC

More ovarian cancer patients benefit from maintenance combined targeted therapy

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC